SUMMARY

During 2014 our Group has worked in the role of murine CD300f in nervous system. By using murine microglial primary cell cultures we have shown that this molecule can acts as a co-activator receptor and suggest that this receptor could play a key role in the regulation of microglial activation. Moreover, by using a model of crush injured sciatic nerve in Thy1-YFP-H mice we demonstrated that the pair CD300f-ligand is implicated in Wallerian degeneration and nerve regeneration by modulating both the influx and phenotype of macrophages. Finally, in collaboration with Dr. Ariel Munitz we have shown that murine CD300f is physically associated with IL-4Ralpha and potently amplifies IL- 4Ralpha-induced responses in vitro and in vivo. Our results establish CD300f as a novel IL-4Ralpha co-receptor. These three works have been already published or are accepted for publication in 2015.

About human CD300f, we are completing the molecular and functional characterization of their physiological ligand. Our data showed that human CD300f acts as a “don’t eat me” receptor tonically activated by their ligand expressed by most of the cells.  This data open the way to target this molecule to activate specific myeloid cells as a therapeutic approach to diverse pathologies.